Development
ASCO: Innovent, Takeda's PD-1/IL-2 bispecific shows 86.4% response rate in early trial for NSCLC
Innovent Biologics (HKEX: 01801), the Suzhou-based biopharmaceutical company, reported preliminary proof-of-concept data from the IBI363 NSCLC trial at the...
Scribe's epigenetic silencer targeting PCSK9 for single-dose LDL reduction enters first human trial
Scribe Therapeutics, an Alameda, California-based biotechnology company, has received clearance from the Australian Therapeutic Goods Administration (TGA)...
Lupeng's rocbrutinib challenges Eli Lilly's Jaypirca in Phase III relapsed refractory CLL trial
Lupeng Pharmaceutical Ltd has enrolled the first patient in the ROCKET-CLL trial, a global Phase III study pitting rocbrutinib (LP-168) directly against Eli...
BioMarin's vosoritide meets primary endpoint in Phase III hypochondroplasia trial
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that vosoritide (Voxzogo) met its primary endpoint in the Phase III CANOPY-HCH-3 study in children with...
Kelun-Biotech's sacituzumab tirumotecan meets primary endpoint in Phase III advanced triple-negative breast cancer trial
Sichuan Kelun-Biotech Biopharmaceutical Co. (HKEx: 6990.HK) announced that its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan met the...
Immix Bio's BCMA CAR-T achieves 95% complete response rate in Phase II AL amyloidosis trial
Immix Biopharma (Nasdaq: IMMX) reported a 95% complete response rate in an interim update from its AL amyloidosis clinical trial, with 19 of 20 evaluable...
Eli Lilly's retatrutide achieves 'surgery-like' 28.3% weight loss in Phase III obesity trial
Eli Lilly (NYSE: LLY) reported that retatrutide, its investigational GIP, GLP-1, and glucagon triple hormone receptor agonist, produced a mean body weight...
Immunovant posts hopeful data for FcRn inhibitor in rheumatoid arthritis post batoclimab failure
Immunovant (Nasdaq: IMVT) reported preliminary Week 16 data from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, showing ACR20, ACR50, and...
HAYA's HTX-001 targets cardiac fibrosis through WISPER lncRNA reprogramming in nHCM patients
HAYA Therapeutics has dosed the first cohort in the Phase I/IIa clinical trial of HTX-001, an antisense oligonucleotide targeting WISPER lncRNA in patients...
Dyne Therapeutics initiates Phase III FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy
Dyne Therapeutics (Nasdaq: DYN) has announced the initiation of the Phase III FORZETTO trial of zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular...
Remepy's drug-software combo produces significant symptoms reduction in Phase IIa Parkinson's disease trial
Remepy reported Phase IIa clinical trial results for Hybridopa (levodopa/carbidopa plus DopApp), its drug-software combination for Parkinson's disease,...
Pfizer's 25vPnC pneumococcal vaccine shows superior serotype 3 responses in Phase II pediatric study
Pfizer (NYSE: PFE) reported Phase II results for its 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in healthy infants, with...
Monopar's Alxn1840 improves copper balance in Phase II Wilson disease trial
Monopar Therapeutics (Nasdaq: MNPR) has announced the publication of Phase II data showing that ALXN1840 (tiomolibdate choline) produced a statistically...
Artiva's allogeneic NK cell therapy achieves 71% ACR50 response in refractory rheumatoid arthritis
Artiva Biotherapeutics (Nasdaq: ARTV) reported that its allogeneic NK cell therapy AB-101 (AlloNK), combined with rituximab, produced a 71% ACR50 response...
Sanofi's efdoralprin alfa outperforms plasma therapy in Phase II alpha-1 antitrypsin deficiency trial
Sanofi (Nasdaq: SNY) reported Phase II data showing efdoralprin alfa, a recombinant human AAT-Fc fusion protein, outperformed standard-of-care...
The AllSci Brief
Systematic R&D and deal news. Daily.